3 Sexy Small-Cap Stocks to Add Sizzle to Your Portfolio
- If you want big returns, you gotta think small – as in small-cap stocks. That's not to say the large-capitalization enterprises can't get you to investment Valhalla.
- 03/10/2024
|
Alphatec Holdings, Inc. (ATEC) Q4 2023 Earnings Call Transcript
- Alphatec Holdings, Inc. (ATEC) Q4 2023 Earnings Call Transcript
- 02/27/2024
|
Alphatec (ATEC) Reports Q4 Loss, Tops Revenue Estimates
- Alphatec (ATEC) came out with a quarterly loss of $0.37 per share versus the Zacks Consensus Estimate of a loss of $0.28. This compares to loss of $0.33 per share a year ago.
- 02/27/2024
|
ATEC Reports Fourth Quarter and Full-Year 2023 Financial Results and Recent Corporate Highlights
- CARLSBAD, Calif.--(BUSINESS WIRE)--Alphatec Holdings, Inc. (Nasdaq: ATEC), a provider of innovative solutions dedicated to revolutionizing the approach to spine surgery, today announced financial results for the quarter and full year ended December 31, 2023, and business highlights. Fourth Quarter and Full Year 2023 Financial Results Quarter EndedDecember 31, 2023 Year EndedDecember 31, 2023 Total revenues $ 138 $ 482 GAAP gross margin 69.0 % 64.3 % Non-GAAP gross margin (prior definiti.
- 02/27/2024
|
Alphatec Holdings: Taking Market Share Amid Strong Execution - Buy
- In recent years, Alphatec Holdings has outperformed expectations on a regular basis and successfully taken share in the $8 billion U.S. spinal disorder treatment market. The company is capitalizing on M&A-related disruptions at key competitors, which has created opportunities for Alphatec to grab additional market share. Persistent cash usage has resulted in substantial debt accumulation and material dilution for common shareholders, but the company appears adequately financed to reach cash flow breakeven by 2025.
- 02/12/2024
|
ATEC to Present at Upcoming Conferences
- CARLSBAD, Calif.--(BUSINESS WIRE)--Alphatec Holdings, Inc. (Nasdaq: ATEC), a provider of innovative solutions dedicated to revolutionizing the approach to spine surgery, announced today that management will participate in the following investor conferences: The Canaccord Genuity Musculoskeletal Conference at the Westin St. Francis Hotel in San Francisco, CA, on February 12, 2024, at 4:00pm PT The Cowen Healthcare Conference at the Marriott Copley Place in Boston, MA, on March 5, 2024, at 2:10pm.
- 01/29/2024
|
ATEC Announces Record Preliminary Revenue Results for 2023 and 2024 Revenue Guidance
- CARLSBAD, Calif.--(BUSINESS WIRE)--Alphatec Holdings, Inc. (Nasdaq: ATEC), a provider of innovative solutions dedicated to revolutionizing the approach to spine surgery, announced today preliminary revenue results for the fourth quarter and full-year ended December 31, 2023, and provided revenue guidance for full-year 2024. Preliminary, Unaudited Fourth Quarter and Full-Year 2023 Revenue Ranges Fourth Quarter Ended December 31, 2023 Full-Year Ended December 31, 2023 Surgical Revenue $121.8M t.
- 01/08/2024
|
Alphatec: Still Not Having My Back
- Alphatec Holdings, Inc.'s focus on growth rather than improving margins raises caution for investors. Despite strong revenue growth, the company continues to experience substantial losses and slow progress on margin improvements. The recent share sales and high debt levels contribute to investor uncertainty about the company's commitment to shareholder value.
- 11/09/2023
|
Alphatec Holdings, Inc. (ATEC) Q3 2023 Earnings Call Transcript
- Alphatec Holdings, Inc. (NASDAQ:ATEC ) Q3 2023 Earnings Conference Call November 6, 2023 4:30 PM ET Company Participants Pat Miles - Chairman and Chief Executive Officer Todd Koning - Chief Financial Officer Conference Call Participants Brooks O'Neil - Lake Street Capital Markets Matt Blackman - Stifel Matthew O'Brien - Piper Sandler Joshua Jennings - TD Cowen Drew Ranieri - Morgan Stanley Sean Lee - H.C. Wainwright Jason Wittes - ROTH Operator Good afternoon, everyone and welcome to the webcast of ATEC's Third Quarter Financial Results.
- 11/06/2023
|
ATEC Reports Third Quarter 2023 Financial Results and Raises Full Year 2023 Adjusted EBITDA Guidance
- CARLSBAD, Calif.--(BUSINESS WIRE)--Alphatec Holdings, Inc. (Nasdaq: ATEC), a provider of innovative solutions dedicated to revolutionizing the approach to spine surgery, today announced financial results for the quarter ended September 30, 2023, and recent corporate highlights. Third Quarter 2023 Financial Results Quarter Ended September 30, 2023 Total revenue $118 million GAAP gross margin 68% Non-GAAP gross margin 72% GAAP operating expenses $118 million Non-GAAP operating expenses $94 mill.
- 11/06/2023
|
ATEC to Participate in Upcoming Investor Conferences
- CARLSBAD, Calif.--(BUSINESS WIRE)--Alphatec Holdings, Inc. (Nasdaq: ATEC), a provider of innovative solutions dedicated to revolutionizing the approach to spine surgery, announced today that management will participate in the following investor events: The Stifel Healthcare Conference at the Lotte New York Palace Hotel in New York, NY, with a fireside chat at 3:00pm ET on November 14, 2023 The Jefferies London Healthcare Conference at the Waldorf Hilton in Aldwych, London, with a fireside chat.
- 11/01/2023
|
ATEC Equipped to Support Ramping Surgical Volume With Proceeds From Secondary Offering
- CARLSBAD, Calif.--(BUSINESS WIRE)--Alphatec Holdings, Inc. (NASDAQ:ATEC), a provider of innovative solutions dedicated to revolutionizing the approach to spine surgery, announced today that the successful close of a $150 million secondary offering on October 27, 2023, positions the Company to accelerate investment in the revenue-generating assets required to capitalize on industry disruption. “We would like to thank our existing and new shareholders for their confidence as we better position AT.
- 10/31/2023
|
ATEC Announces Closing of Public Stock Offering
- CARLSBAD, Calif.--(BUSINESS WIRE)--Alphatec Holdings, Inc. (“ATEC”) (NASDAQ: ATEC), a provider of innovative solutions dedicated to revolutionizing the approach to spine surgery, today announced the closing of its previously announced underwritten public offering of 14,300,000 shares of its common stock at a public offering price of $10.50 per share. Morgan Stanley, TD Cowen, Barclays and Stifel acted as joint book-running managers in the offering. ATEC received gross proceeds from the offering.
- 10/27/2023
|
Why Alphatec Holdings Stock Plunged Today
- Alphatec just priced an offering of 14.3 million shares at $10.50 per share -- a more than 18% discount from yesterday's close. The offering was filed pursuant to a previously filed shelf registration statement by the company.
- 10/25/2023
|
ATEC Announces Pricing of Public Offering of Common Stock
- CARLSBAD, Calif.--(BUSINESS WIRE)--Alphatec Holdings, Inc. (“ATEC”) (NASDAQ: ATEC), a provider of innovative solutions dedicated to revolutionizing the approach to spine surgery, today announced the pricing of an underwritten public offering of 14,300,000 shares of its common stock at a public offering price of $10.50 per share. The offering is expected to close on October 27, 2023, subject to the satisfaction of customary closing conditions. In connection with the offering, ATEC has granted th.
- 10/24/2023
|
Alphatec: Price Reversal Diverges From Economic Levers That Are Well In Situ (Rating Upgrade)
- Alphatec Holdings' Q2 numbers were strong, posting another double-digit upside at the top line. The company's surgical segment, particularly the LTP procedure, shows promise for growth and profitability in my view. Sentiment towards Alphatec's stock is mixed, with bullish positioning in the short-term but potential downside in the long term.
- 08/10/2023
|
Alphatec Holdings, Inc. (ATEC) Q2 2023 Earnings Call Transcript
- Alphatec Holdings, Inc. (NASDAQ:ATEC ) Q2 2023 Earnings Conference Call August 3, 2023 4:30 PM ET Company Participants Pat Miles - Chairman and CEO Todd Koning - CFO Conference Call Participants Matt Blackman - Stifel Josh Jennings - TD Cowen Andrew Ranieri - Morgan Stanley David Saxon - Needham & Co. Aaron Wukmir - Lake Street Capital Markets Sean Lee - H.C. Wainwright Operator Good afternoon, everyone.
- 08/06/2023
|
Alphatec (ATEC) Reports Q2 Loss, Tops Revenue Estimates
- Alphatec (ATEC) came out with a quarterly loss of $0.43 per share versus the Zacks Consensus Estimate of a loss of $0.30. This compares to loss of $0.36 per share a year ago.
- 08/03/2023
|
Medical Technology Stock Breaks Out, Sees 28% Revenue Growth
- Medical technology company sees 20% long-term growth as it expands into new global markets. Management projects positive cash flow in 2025.
- 06/27/2023
|
Alphatec (ATEC) Surges 8.8%: Is This an Indication of Further Gains?
- Alphatec (ATEC) saw its shares surge in the last session with trading volume being higher than average. The latest trend in earnings estimate revisions may not translate into further price increase in the near term.
- 06/27/2023
|
Alphatec: A Balancing Act
- Alphatec continues to see strong growth in the spine market. Sales growth is to be applauded, but margins remain the issue, with no progress seen on this front.
- 05/08/2023
|
Alphatec Holdings, Inc. (ATEC) Q1 2023 Earnings Call Transcript
- Alphatec Holdings, Inc. (NASDAQ:ATEC ) Q1 2023 Earnings Conference Call May 4, 2023 4:30 PM ET Company Participants Pat Miles - Chairman and CEO Todd Koning - Chief Financial Officer Conference Call Participants Matt Blackman - Stifel Brooks O'Neil - Lake Street Capital Markets Eric Anderson - TD Cowen Sean Lee - H.C. Wainwright Operator Good afternoon, everyone.
- 05/06/2023
|
Artificial Intelligence Engine Predicts ATEC Stock to Gain 5.5% by June 1
- The world's foremost artificial intelligence stock trading algorithm, An-E, predicts that Alphatec (NASDAQ: ATEC ) stock will gain 5.5% by June 1. An-E (pronounced Annie) has made this kind of prediction before.
- 05/04/2023
|
Alphatec's $14 million deposited with SVB represents more than 16% of its cash, cash equivalents
- Shares of Alphatec Holdings Inc. ATEC, gained 0.2% in morning trading Monday, after the California-based spinal fusion technology company disclosed that it had $14 million deposited with SVB Financial Group's SIVB, Silicon Valley Bank for use for its day-to-day operations. That represented about 16.5% of the $84.7 million Alphatec had in cash and cash equivalents as of Dec. 31.
- 03/13/2023
|
Alphatec (ATEC) Reports Q4 Loss, Tops Revenue Estimates
- Alphatec (ATEC) delivered earnings and revenue surprises of -10% and 0.23%, respectively, for the quarter ended December 2022. Do the numbers hold clues to what lies ahead for the stock?
- 02/28/2023
|
Alphatec (ATEC) Soars 8.4%: Is Further Upside Left in the Stock?
- Alphatec (ATEC) saw its shares surge in the last session with trading volume being higher than average. The latest trend in earnings estimate revisions may not translate into further price increase in the near term.
- 02/10/2023
|
Examining The Recent Breakout For Alphatec Holdings (Technical Analysis)
- Alphatec has broken out to the upside following a charge off its July FY22 lows. The rally has extended to the present day, and we examined to see if it has the legs to extend further.
- 01/07/2023
|
ATEC to Participate in Upcoming Investor Conference
- CARLSBAD, Calif.--( BUSINESS WIRE )--Alphatec Holdings, Inc. (Nasdaq: ATEC), a provider of innovative solutions dedicated to revolutionizing the approach to spine surgery, announced today that management will virtually participate in the 25th Annual Needham Growth Conference with a fireside chat on January 12, 2023, at 3:00p.m. ET. The webcast of the presentation and an archived recording will be available in the Investor Relations Section of the Company's website.
- 12/28/2022
|
Alphatec Holdings, Inc. (ATEC) Q3 2022 Earnings Call Transcript
- Alphatec Holdings, Inc. (NASDAQ:ATEC ) Q3 2022 Earnings Conference Call November 3, 2022 4:30 PM ET Company Participants Pat Miles - Chairman and Chief Executive Officer Todd Koning - Chief Financial Officer Conference Call Participants Phillip Dantoin - Piper Sandler Young Li - Jefferies Brooks O'Neil - Lake Street Capital Markets Drew Ranieri - Morgan Stanley Eric Anderson - Cowen Caitlin Cronin - Canaccord Genuity David Saxon - Needham & Company Jason Wittes - Loop Capital Operator Good afternoon, everyone and welcome to the webcast of ATEC's Third Quarter Financial Results. We would like to remind everyone that participants on the call will make forward-looking statements.
- 11/06/2022
|
Alphatec (ATEC) Reports Q3 Loss, Tops Revenue Estimates
- Alphatec (ATEC) delivered earnings and revenue surprises of -9.38% and 3.18%, respectively, for the quarter ended September 2022. Do the numbers hold clues to what lies ahead for the stock?
- 11/03/2022
|
Alphatec: Not Having My Back (Yet)
- Alphatec has seen solid growth in its spine business. Strong growth is very encouraging, yet lack of margin developments make me very hesitant.
- 10/15/2022
|
Alphatec (ATEC) Soars 7%: Is Further Upside Left in the Stock?
- Alphatec (ATEC) witnessed a jump in share price last session on above-average trading volume. The latest trend in earnings estimate revisions for the stock suggests that there could be more strength down the road.
- 09/29/2022
|
Alphatec Holdings, Inc. (ATEC) CEO Pat Miles on Q2 2022 Results - Earnings Call Transcript
- Alphatec Holdings, Inc. (NASDAQ:ATEC ) Q2 2022 Results Conference Call August 4, 2022 4:30 PM ET Company Participants Pat Miles - Chairman & Chief Executive Officer Todd Koning - Chief Financial Officer Conference Call Participants Eric Anderson - Cowen Colin Clark - Stifel Gibran Ahmed - Canaccord Joseph Conway - Needham and Company Phillip Dantoin - Piper Sandler Operator Good afternoon, everyone, and welcome to the webcast of ATEC's Second Quarter Financial Results. We would like to remind everyone that participants on the call will make forward-looking statements.
- 08/06/2022
|
Alphatec (ATEC) Reports Q2 Loss, Tops Revenue Estimates
- Alphatec (ATEC) delivered earnings and revenue surprises of -2.86% and 7.80%, respectively, for the quarter ended June 2022. Do the numbers hold clues to what lies ahead for the stock?
- 08/04/2022
|
Alphatec: Profitability, FCF, Valuation A Concern Amid Macro-Climate
- Alphatec has weakened against the benchmark and sector peers in FY22 and continues to display forward-looking downside. A series of operating and FCF losses have put the company out of favour with investors, who are searching for profitability and high quality instead.
- 07/20/2022
|
Why Alphatec Holdings Shares Are Getting Hammered Today
- Alphatec Holdings Inc (NASDAQ: ATEC) shares are trading lower by 14.48% to $6.77 Thursday morning after Bonitas Research released a short report on the stock. Bonitas Research Thursday morning tweeted: "Bonitas is short $ATEC.
- 07/14/2022
|
Alphatec Holdings, Inc. (ATEC) CEO Pat Miles on Q1 2022 Results - Earnings Call Transcript
- Alphatec Holdings, Inc. (NASDAQ:ATEC ) Q1 2022 Earnings Conference Call May 5, 2022 4:30 PM ET Company Participants Pat Miles - Chairman & Chief Executive Officer Todd Koning - Chief Financial Officer Conference Call Participants Brooks O'Neil - Lake Street Capital Markets Jason Wittes - Loop Phil Coover - Goldman Sachs Sean Lee - H.C. Wainwright Joshua Jennings - Cowen Operator Good afternoon, everyone and welcome to the webcast of ATEC's First Quarter of 2022 Financial Results.
- 05/08/2022
|
Alphatec (ATEC) Reports Q1 Loss, Tops Revenue Estimates
- Alphatec (ATEC) delivered earnings and revenue surprises of -48.28% and 4.74%, respectively, for the quarter ended March 2022. Do the numbers hold clues to what lies ahead for the stock?
- 05/05/2022
|
Strength Seen in Alphatec (ATEC): Can Its 12.1% Jump Turn into More Strength?
- Alphatec (ATEC) witnessed a jump in share price last session on above-average trading volume. The latest trend in earnings estimate revisions for the stock doesn't suggest further strength down the road.
- 04/04/2022
|
We see opportunities in industrials or industrial tech, says Nancy Prial
- Nancy Prial, Essex Investment Management, joins 'The Exchange' to discuss where she's seeing market opportunities right now.
- 03/07/2022
|
Alphatec Holdings, Inc. (ATEC) CEO Pat Mile on Q4 2021 Results - Earnings Call Transcript
- Alphatec Holdings, Inc. (ATEC) CEO Pat Mile on Q4 2021 Results - Earnings Call Transcript
- 03/01/2022
|
Alphatec (ATEC) Reports Q4 Loss, Tops Revenue Estimates
- Alphatec (ATEC) delivered earnings and revenue surprises of -29.03% and 0.36%, respectively, for the quarter ended December 2021. Do the numbers hold clues to what lies ahead for the stock?
- 03/01/2022
|
ATEC to Report Fourth Quarter and Fiscal Year 2021 Financial Results on March 1, 2022
- CARLSBAD, Calif.--(BUSINESS WIRE)--Alphatec Holdings, Inc. (Nasdaq: ATEC), a provider of innovative spine surgery solutions dedicated to revolutionizing the approach to spine surgery, announced today that it will report fourth quarter and full year 2021 financial results on March 1, 2022, after the market close. The Company will host a live webcast that day at 1:30 p.m. PT / 4:30 p.m. ET. Webcast To access the live webcast, please visit the Investor Relations Section of ATEC's Corporate Website
- 02/07/2022
|
Alphatec (ATEC) Moves 12.8% Higher: Will This Strength Last?
- Alphatec (ATEC) saw its shares surge in the last session with trading volume being higher than average. The latest trend in earnings estimate revisions may not translate into further price increase in the near term.
- 01/11/2022
|
5 Stocks Insiders Are Still Buying (Even As Others Cash Out)
- Insider sales are generally a sign the market is about to drop, but not everyone's selling. Here are five companies with insider buying.
- 11/12/2021
|
Alphatec Holdings, Inc. (ATEC) CEO Patrick Miles on Q3 2021 Results - Earnings Call Transcript
- Alphatec Holdings, Inc. (ATEC) CEO Patrick Miles on Q3 2021 Results - Earnings Call Transcript
- 11/07/2021
|
ATEC to Feature Comprehensive Procedural Solutions at NASS 2021
- CARLSBAD, Calif.--(BUSINESS WIRE)-- #ATEC--Alphatec Holdings, Inc. (Nasdaq: ATEC), a provider of innovative solutions dedicated to revolutionizing the approach to spine surgery, announced today that the Company's comprehensive procedural portfolio will be featured at the North American Spine Society (NASS) Annual Meeting, which will be held at the Boston Convention and Exhibition Center from September 29 through October 1, 2021. “We are excited to feature the breadth of clinically distinct products and
- 09/15/2021
|
This Revolutionary Medical Device Company Goes to 11
- To stand tall against a competitive market, NuVasive depends on a strong spinal platform.
- 08/13/2021
|
Alphatec Holdings: Buy With Both Hands As Business Momentum Continues To Build
- Alphatec Holdings: Buy With Both Hands As Business Momentum Continues To Build
- 08/12/2021
|
Alphatec Holdings, Inc. (ATEC) CEO Patrick Miles on Q2 2021 Results - Earnings Call Transcript
- Alphatec Holdings, Inc. (ATEC) CEO Patrick Miles on Q2 2021 Results - Earnings Call Transcript
- 08/04/2021
|
Alphatec (ATEC) Reports Q2 Loss, Tops Revenue Estimates
- Alphatec (ATEC) delivered earnings and revenue surprises of -50.00% and 21.58%, respectively, for the quarter ended June 2021. Do the numbers hold clues to what lies ahead for the stock?
- 08/03/2021
|
Earnings Preview: Alphatec (ATEC) Q2 Earnings Expected to Decline
- Alphatec (ATEC) doesn't possess the right combination of the two key ingredients for a likely earnings beat in its upcoming report. Get prepared with the key expectations.
- 07/27/2021
|
New Strong Sell Stocks for July 15th
- ATEC, DRNA, AG, PAX, and AUPH have been added to the Zacks Rank #5 (Strong Sell) List on July 15, 2021
- 07/15/2021
|
Alphatec - Strong Momentum, Still Concerns
- After a troubled past, Alphatec has seen huge sales traction over the past two years. Rapid growth in a Covid-19-impacted market shows real strength, albeit that losses have not come down yet.
- 07/15/2021
|
ATEC Announces Select Preliminary Second Quarter 2021 Financial Results
- Second quarter 2021 U.S. organic revenue expected to range from $55.4 million to $56.0 million
- 07/12/2021
|
ATEC Appoints Marie Meynadier, Ph.D., to Board of Directors
- CARLSBAD, Calif., June 21, 2021 (GLOBE NEWSWIRE) -- Alphatec Holdings, Inc. (Nasdaq: ATEC), a provider of innovative solutions dedicated to revolutionizing the approach to spine surgery, announced today that Marie Meynadier, Ph.D., founder of EOS imaging, has been appointed as an independent director to the ATEC Board.
- 06/21/2021
|
Strong Success of the Tender Offer Initiated by Alphatec Holdings for Common Shares and OCEANEs of EOS IMAGING
- ATEC secures ~89% of EOS common shares and voting rights as of May 13, 2021 ATEC secures ~89% of EOS common shares and voting rights as of May 13, 2021
- 05/12/2021
|
Alphatec Holdings' (ATEC) CEO Pat Miles on Q1 2021 Results - Earnings Call Transcript
- Alphatec Holdings' (ATEC) CEO Pat Miles on Q1 2021 Results - Earnings Call Transcript
- 05/08/2021
|
Alphatec (ATEC) Reports Q1 Loss, Tops Revenue Estimates
- Alphatec (ATEC) delivered earnings and revenue surprises of 15.79% and 0.05%, respectively, for the quarter ended March 2021. Do the numbers hold clues to what lies ahead for the stock?
- 05/06/2021
|
ATEC to Report First Quarter Financial Results on May 6, 2021
- CARLSBAD, Calif., April 19, 2021 (GLOBE NEWSWIRE) -- Alphatec Holdings, Inc. (Nasdaq: ATEC), a provider of innovative spine surgery solutions dedicated to revolutionizing the approach to spine surgery, announced today that it will report first quarter 2021 financial results on May 6, 2021, after the market close. The Company will host a live webcast that day at 1:30 p.m. PT / 4:30 p.m. ET.
- 04/19/2021
|
Alphatec (ATEC) Surges 11.4%: Is This an Indication of Further Gains?
- Alphatec (ATEC) saw its shares surge in the last session with trading volume being higher than average. The latest trend in earnings estimate revisions may not translate into further price increase in the near term.
- 04/09/2021
|
ATEC Announces Preliminary First Quarter 2021 Revenue Results and Provides Corporate Updates
- First quarter 2021 U.S. revenue grows approximately 50% compared to last year
- 04/08/2021
|
Top Wall Street analysts are unanimously bullish on these stocks
- TipRanks analyst ranking service pinpoints Wall Street's best-performing stocks, like Amazon and Microsoft
- 03/21/2021
|
Alphatec Holdings, Inc. (ATEC) CEO Patrick Miles on Q4 2020 Results - Earnings Call Transcript
- Alphatec Holdings, Inc. (ATEC) CEO Patrick Miles on Q4 2020 Results - Earnings Call Transcript
- 03/05/2021
|
Alphatec (ATEC) Reports Q4 Loss, Tops Revenue Estimates
- Alphatec (ATEC) delivered earnings and revenue surprises of 4.35% and 0.19%, respectively, for the quarter ended December 2020. Do the numbers hold clues to what lies ahead for the stock?
- 03/04/2021
|
Alphatec Holdings: Q4 Earnings Insights
- Shares of Alphatec Holdings (NASDAQ:ATEC) moved higher in after-market trading after the company reported Q4 results. Quarterly Results Earnings per share fell 50.00% year over year to ($0.27), which missed the estimate of ($0.21).
- 03/04/2021
|
ATEC Reports Fourth Quarter and Full Year 2020 Financial Results and Recent Corporate Highlights
- CARLSBAD, Calif., March 04, 2021 (GLOBE NEWSWIRE) -- Alphatec Holdings, Inc. (Nasdaq: ATEC), a provider of innovative solutions dedicated to revolutionizing the approach to spine surgery, today announced financial results for the quarter and year ended December 31, 2020, and recent corporate highlights.
- 03/04/2021
|
Earnings Preview: Alphatec Holdings
- On Thursday, March 04, Alphatec Holdings (NASDAQ:ATEC) will report its last quarter's earnings. Here is Benzinga's preview of the company's release.
- 03/03/2021
|
ATEC to Report Fourth Quarter and Full Year 2020 Financial Results on March 4, 2021
- CARLSBAD, Calif., Feb. 08, 2021 (GLOBE NEWSWIRE) -- Alphatec Holdings, Inc. (Nasdaq: ATEC), a provider of innovative spine surgery solutions dedicated to revolutionizing the approach to spine surgery, announced today that it will report fourth quarter and full year 2020 financial results on March 4, 2021, after the market close. The Company will host a live webcast the same day at 1:30 p.m. PT / 4:30 p.m. ET.
- 02/08/2021
|
ATEC Opens New Headquarters with Substantially Increased Sales and Surgeon Education Capacity
- CARLSBAD, Calif., Feb. 01, 2021 (GLOBE NEWSWIRE) -- Alphatec Holdings, Inc. (Nasdaq: ATEC), a provider of innovative spine surgery solutions dedicated to revolutionizing the approach to spine surgery, announced today that the Company has relocated to its new headquarters in Carlsbad.
- 02/01/2021
|
4 Affordable Breakout Stocks for Stunning Returns
- Selecting breakout stocks continues to be one of the most popular methods utilized by active investors.
- 01/06/2021
|
3 Stocks to Watch Out for Earnings Acceleration in 2021
- It's prudent for investors to keep an eye on a few stocks like Alphatec Holdings (ATEC), Fidus Investment (FDUS) and Blue Bird (BLBD) for stellar earnings acceleration.
- 01/06/2021
|
5 Little-Known Stocks Under $20 Analysts Recommend Buying
- We recommend a few lesser-known stocks that hold promise for high returns this year. ADTN, AMEH, ATEC, DFIN and DGII fit the bill.
- 01/04/2021
|
ATEC to Present at the H.C. Wainwright Virtual BioConnect 2021 Conference
- CARLSBAD, Calif., Jan. 04, 2021 (GLOBE NEWSWIRE) -- Alphatec Holdings, Inc. (Nasdaq: ATEC), a provider of innovative spine surgery solutions dedicated to revolutionizing the approach to spine surgery, announced today that Jeff Black, Executive Vice President and Chief Financial Officer, will present virtually at the H.C. Wainwright BioConnect 2021 Conference, which will be held January 11 through 14, 2021. The pre-recorded presentation will be accessible on demand for 90 days beginning January 11, 2021, at 6 A.M. ET via this link . The accompanying presentation materials will be available from the Investor Relations page of the Company's corporate website at www.atecspine.com.
- 01/04/2021
|
ATEC Continues to Advance Clinical Prowess with Renewed Agreement to Acquire EOS Imaging
- CARLSBAD, Calif., Dec. 16, 2020 (GLOBE NEWSWIRE) -- Alphatec Holdings, Inc. (“ATEC” or the “Company”) (Nasdaq: ATEC), a medical device company dedicated to revolutionizing the approach to spine surgery, announced today that it has entered into an agreement to acquire EOS imaging, SA, for a purchase price of $79.7 million, plus the retirement debt of $37.2 million, in an all-cash transaction.
- 12/17/2020
|
ATEC to Participate in Upcoming Investor Conferences
- CARLSBAD, Calif., Nov. 11, 2020 (GLOBE NEWSWIRE) -- Alphatec Holdings, Inc. (Nasdaq: ATEC) (the “Company”), a provider of innovative spine surgery solutions dedicated to revolutionizing the approach to spine surgery, announced today that Pat Miles, Chief Executive Officer, and Jeff Black, Chief Financial Officer, will virtually participate in the following upcoming investor conferences.
- 11/11/2020
|
Alphatec Holdings, Inc.'s (ATEC) CEO Pat Miles on Q3 2020 Results - Earnings Call Transcript
- Alphatec Holdings, Inc.'s (ATEC) CEO Pat Miles on Q3 2020 Results - Earnings Call Transcript
- 11/07/2020
|
Preview: Alphatec Holdings's Earnings
- On Thursday, November 05, Alphatec Holdings (NASDAQ: ATEC) will report its last quarter's earnings. Here is Benzinga's preview of the company's release.
- 11/04/2020
|
ATEC Extends InVictus MIS Platform With Commercial Release of InVictus MIS Tower
- Elevates MIS posterior fixation optionality Robust instrumentation designed to treat more complex pathologies less invasively CARLSBAD, Calif.,...
- 10/19/2020
|
12 Healthcare Stocks Moving In Friday's After-Market Session
- Gainers
InVivo Therapeutics Hldg (NASDAQ:NVIV) shares rose 11.11% to $1.5 during Friday's after-market session. InVivo Therapeutics Hldg's trading volume hit 1.4K shares...
- 10/16/2020
|
55,250 Shares in Alphatec Holdings, Inc. (NASDAQ:ATEC) Purchased by CX Institutional
- CX Institutional acquired a new position in shares of Alphatec Holdings, Inc. (NASDAQ:ATEC) during the 3rd quarter, according to the company in its most recent filing with the Securities & Exchange Commission. The institutional investor acquired 55,250 shares of the medical technology company’s stock, valued at approximately $367,000. A number of other institutional investors and […]
- 10/15/2020
|
A Look Into Alphatec's Debt
- Shares of Alphatec Holdings (NASDAQ: ATEC) moved higher by 83.99% in the past three months. Before we understand the importance of debt, let us look at how much debt Alphatec...
- 10/14/2020
|
Alphatec Holdings (ATEC) Receives a Buy from Canaccord Genuity - Markets
- Canaccord Genuity analyst Kyle Rose maintained a Buy rating on Alphatec Holdings (ATEC – Research Report) on October 11 and
- 10/13/2020
|
12 Healthcare Stocks Moving In Tuesday's After-Market Session
- Gainers
Genesis Healthcare (NYSE:GEN) stock moved upwards by 39.15% to $0.73 during Tuesday's after-market session. At the close, Genesis Healthcare's trading volume...
- 10/13/2020
|
Alphatec (NASDAQ:ATEC) Reaches New 12-Month High After Analyst Upgrade
- Alphatec Holdings Inc (NASDAQ:ATEC)’s stock price hit a new 52-week high during mid-day trading on Friday after Lake Street Capital raised their price target on the stock from $13.00 to $15.00. Lake Street Capital currently has a buy rating on the stock. Alphatec traded as high as $10.06 and last traded at $9.87, with a […]
- 10/10/2020
|
Alphatec Pops 21% On 3Q Sales Guidance Beat; Street Says Buy
- Shares in Alphatec Holdings are spiking 21% in Thursday’s pre-market market session after the medical device company surprised investors with preliminary
- 10/08/2020
|
U.S. stocks higher at close of trade; Dow Jones Industrial Average up 0.43%
- U.S. stocks higher at close of trade; Dow Jones Industrial Average up 0.43%
- 10/08/2020
|
Stryker Marks One Million Mesa Pedicle Screw Implantations Globally
- Stryker marks one million Mesa Pedicle Screw Implantations globally, and will virtually showcase Mesa at the NASS annual meeting, Oct. 6-9.
- 10/05/2020
|
Alphatec Holdings (ATEC) Investor Presentation - Slideshow
- The following slide deck was published by Alphatec Holdings, Inc. in conjunction with this event..
- 08/17/2020
|
Alphatec : 2020 Annual Meeting of Stockholders | MarketScreener
|
ATEC Reports Second Quarter 2020 Financial Results and Recent Corporate Highlights
- • U.S. Revenue Grows 11% • Seventh Consecutive Quarter of Year-Over-Year Double-Digit Revenue IncreaseCARLSBAD, Calif., Aug. 06, 2020 (GLOBE NEWSWIRE) -- Alphatec Holdings, Inc. (“ATEC” or the “Company”) (Nasdaq: ATEC), a provider of innovative spine surgery solutions dedicated to revolutionizing the approach to spine surgery, today announced financial results for the quarter ended June 30, 2020, and recent corporate highlights.Second Quarter 2020 Financial Results * Total revenue of $29.6 million; U.S. revenue of $28.8 million, up 11% year-over-year; * U.S. gross margin of 72.3%; and * Cash and cash equivalents of $31.2 million as of June 30, 2020.Recent Corporate Highlights * Increased contribution from new products to 61% of Q2 U.S. revenue, up from 32% in Q2 2019; * Increased U.S. revenue and average product categories sold per case year-over-year by 14%, more than offsetting 4% decrease in surgery volume; * Continued sales network transformation, resulting in 15% year-over-year revenue growth from strategic distribution; * Increased revenue from top 20 surgeons by 25% year-over-year; and * Commenced significant upgrades of ATEC cervical portfolio sophistication with FDA 510(k) clearance of the InsigniaTM Anterior Cervical Plate System and InVictusTM CT Spinal Fixation System, which expands the elegance of InVictus across cervical, thoracic and lumbar procedures.“I am proud of the way our team continues to methodically execute the plan,” said Pat Miles, Chairman and Chief Executive Officer. “Three years ago, we committed to creating clinical distinction, compelling surgeon adoption and revitalizing our sales channel. We described a time when unmatched procedural innovation would attract an increasingly influential surgeon base and a more professionalized salesforce, which would lead to increased case complexity, more products per procedure, and improved revenue per surgery. We’re beginning to see this vision reflected in our financial performance. While other companies commit to advertising campaigns, our commitment is to improving spine care. We are just getting started. We expect to see continued strong interest and enthusiasm for the 8 to 10 new solutions we will deliver in the second half of 2020. We could not be more viscerally and personally engaged in our mission and our ability to continue to drive industry-leading growth. We know our best is yet to come.” Comparison of Selected GAAP and Non-GAAP Financial Results for the Second Quarter 2020 to Second Quarter 2019Revenue from U.S. products for the second quarter 2020 was $28.8 million, up 11% compared to $26.1 million in the second quarter 2019. Revenue growth generated by new products and the strategic distribution channel continues to outpace the ongoing revenue impacts of transitioning or discontinuing non-strategic distributor relationships.Gross profit and gross margin from U.S. products for the second quarter 2020 were $20.8 million and 72.3%, respectively, compared to $18.8 million and 72.2%, respectively, for the second quarter 2019. On a non-GAAP basis, excluding non-cash excess and obsolete charges, U.S. gross margin was 78.2% in the second quarter of 2020, compared to 80.6% in the second quarter 2019. Non-GAAP U.S. gross margin was impacted by product mix and amortization of SafeOp-related intangibles, which commenced in late 2019.Total operating expenses for the second quarter 2020 were $32.0 million compared to $29.3 million in the second quarter 2019. On a non-GAAP basis, excluding stock-based compensation, fair value adjustments, litigation-related expenses and transaction-related expenses, total operating expenses increased to $26.4 million from $25.8 million in 2019, reflecting increased selling costs from U.S. revenue growth, as well as increased investments in organic product development to support new product launches.Non-GAAP adjusted operating loss, which excludes stock-based compensation, fair value adjustments, litigation-related expenses, transaction-related expenses and excess and obsolescence charges, was $3.7 million for the second quarter 2020, compared to a loss of $4.7 million for the second quarter 2019.Non-GAAP adjusted EBITDA, which excludes stock-based compensation, fair value adjustments, litigation-related expenses, transaction-related expenses and excess and obsolescence charges in the second quarter 2020 was a loss of $1.1 million, compared to a loss of $3.0 million in the second quarter 2019. For more detailed information on non-GAAP operating expenses, non-GAAP adjusted operating loss and non-GAAP adjusted EBITDA, please refer to the table, “Alphatec Holdings, Inc. Reconciliation of Non-GAAP Financial Measures,” that follows.Cash and cash equivalents at June 30, 2020 were $31.2 million, with an additional $25 million available under the credit facility with Squadron Capital (the “Squadron facility”).Current and long-term debt at face value as of June 30, 2020 includes $75 million in term debt under the Squadron facility. During the second quarter of 2020, the Company retired its revolving credit facility with MidCap Funding.2020 Financial OutlookAs a result of hospitals globally postponing elective procedures to preserve capacity for COVID-19 patients, ATEC suspended its previously announced 2020 revenue guidance on April 8, 2020. While recovery of surgical volumes has been more robust than initially anticipated, the Company continues to have limited visibility into any continuing or future impact of the global pandemic.Investor Conference CallATEC will present the results via a live webcast today at 1:30 p.m. PT / 4:30 p.m. ET to discuss the results. At that time, please click here to access the live webcast. An audiocast of the presentation will be also be available domestically at (877) 556-5251 and internationally at (720) 545-0036. The conference ID number is 5682075.A replay of the webcast will remain available on ATEC’s corporate website at www.atecspine.com until the Company releases second quarter financial results. In addition, a replay of the audiocast will be available until August 14, 2020. The replay dial-in numbers are (855) 859-2056 for domestic callers and (404) 537-3406 for international callers. Please use the replay conference ID number 5682075.Non-GAAP Financial InformationTo supplement the Company’s financial statements presented in accordance with U.S. generally accepted accounting principles (GAAP), the Company reports certain non-GAAP financial measures, including non-GAAP U.S. gross margin, non-GAAP operating expenses, non-GAAP operating loss, and non-GAAP Adjusted EBITDA. The Company believes that these non-GAAP financial measures provide investors with an additional tool for evaluating the Company's core performance, which management uses in its own evaluation of continuing operating performance, and a baseline for assessing the future earnings potential of the Company. The Company’s non-GAAP financial measures may not provide information that is directly comparable to that provided by other companies in the Company’s industry, as other companies in the industry may calculate non-GAAP financial results differently, particularly related to non-recurring, unusual items. Non-GAAP financial results should be considered in addition to, and not as a substitute for, or superior to, financial measures calculated in accordance with GAAP. Included below are reconciliations of the non-GAAP financial measures to the comparable GAAP financial measures.Filing of Shelf Registration Statement on Form S-3 The Company intends to file a “universal shelf” registration statement on Form S-3 (the “Registration Statement”) with the United States Securities and Exchange Commission (“SEC”). ATEC equity securities may not be sold, nor may offers to buy the securities under the Registration Statement be accepted, prior to the time the Registration Statement becomes effective by the SEC. If the Registration Statement is declared effective, ATEC may offer and sell, from time to time, up to $200 million, separately or together, of its securities. The terms of any such offering, including the specific terms and prices of the securities, will be determined at the time of such offering and be made solely by means of the prospectus included in the Registration Statement and any prospectus supplement that may be filed with the SEC relating to such offering. This press release shall not constitute an offer to sell or the solicitation of an offer to buy, nor shall there be any sale of the Securities in any state in which such offer, solicitation or sale would be unlawful prior to registration or qualification under the securities law of any such state.On August 6, 2020, ATEC entered into an “at-the-market” (“ATM”) Sales Agreement with Cowen. Under the ATM Sales Agreement, ATEC may sell its common shares from time to time, for up to $50 million, separately or together, in aggregate sales proceeds in “at-the-market” transactions. While ATEC has no current need to utilize the Registration Statement to issue its securities, under the ATM Sales Agreement or otherwise, the Registration Statement will provide ATEC with added flexibility to strategically access capital markets.About Alphatec Holdings, Inc.Alphatec Holdings, Inc. (“ATEC”), through its wholly-owned subsidiaries, Alphatec Spine, Inc. and SafeOp Surgical, Inc., is a medical device company dedicated to revolutionizing the approach to spine surgery through clinical distinction. ATEC architects and commercializes approach-based technology that integrates seamlessly with the SafeOp Neural InformatiX System to provide real-time, objective nerve information that can enhance the safety and reproducibility of spine surgery. Additional information can be found at www.atecspine.com.Additional information can be found at www.
- 08/06/2020
|
Alphatec to Participate in 40th Annual Canaccord Growth Conference
- CARLSBAD, Calif., July 31, 2020 (GLOBE NEWSWIRE) -- Alphatec Holdings, Inc. (Nasdaq: ATEC) (“Alphatec” or the “Company”), a provider of innovative spine surgery solutions dedicated to revolutionizing the approach to spine surgery, announced today that Pat Miles, Chief Executive Officer, will present virtually at the 40th Annual Canaccord Growth Conference on August 12, 2020, at 1 P.M. EDT. Management will also participate in virtual one-on-one meetings with investors who are registered to attend the conference.A live audio webcast of the conference presentation, along with copies of the accompanying presentation materials, will be available online from the Investor Relations page of the Company's corporate website at www.atecspine.com. The webcast replay will be archived under the “Investor Presentations” link for 90 days following the conference. About Alphatec Holdings, Inc.Alphatec Holdings, Inc. (ATEC), through its wholly-owned subsidiaries, Alphatec Spine, Inc. and SafeOp Surgical, Inc., is a medical device company dedicated to revolutionizing the approach to spine surgery through clinical distinction. ATEC architects and commercializes approach-based technology that integrates seamlessly with the SafeOp Neural InformatiX System to provide real-time, objective nerve information that can enhance the safety and reproducibility of spine surgery. Additional information can be found at www.atecspine.com.Forward-Looking StatementsStatements made during the investor events referenced herein may contain "forward-looking statements" within the meaning of the Private Securities Litigation Reform Act of 1995 that involve risks and uncertainty. Such statements are based on management's current expectations and are subject to many risks and uncertainties that could cause actual results to differ materially from those described in the forward-looking statements. These and other forward-looking statements are not guarantees of future results and are subject to risks, uncertainties, and assumptions that could cause actual results to differ materially from those expressed in any forward-looking statements. A list and description of such factors, risks and uncertainties can be found in the Company’s most recent annual report, and any subsequent quarterly and current reports, filed with the Securities and Exchange Commission. ATEC disclaims any intention or obligation to update or revise any forward-looking statements, whether as a result of new information, future events, or otherwise unless required by law.Investor/Media Contact: Josh Berg Investor Relations (760) 494-6790 ir@atecspine.com Company Contact: Jeff Black Chief Financial Officer ir@atecspine.com
- 07/31/2020
|
Analysts Estimate Alphatec (ATEC) to Report a Decline in Earnings: What to Look Out for
- Alphatec (ATEC) doesn't possess the right combination of the two key ingredients for a likely earnings beat in its upcoming report. Get prepared with the key expectations.
- 07/30/2020
|
Alphatec to Report Second Quarter 2020 Financial Results on August 6, 2020
- CARLSBAD, Calif., July 23, 2020 (GLOBE NEWSWIRE) -- Alphatec Holdings, Inc. (Nasdaq: ATEC) (“ATEC” or the “Company”), a provider of innovative spine surgery solutions dedicated to revolutionizing the approach to spine surgery, announced today that it will release second quarter financial results on Thursday, August 6, 2020, after the market close. The Company will present the results via a live webcast on Thursday, August 6, 2020, at 1:30 p.m. PT / 4:30 p.m. ET. The live webcast will be accessible via this link. An audiocast of the presentation will also be available domestically at (877) 556-5251 and internationally at (720) 545-0036. The conference ID number is 5682075.A replay of the webcast will remain available on ATEC’s corporate website at www.atecspine.com until the Company releases third quarter financial results. In addition, a replay of the audiocast will be available until August 14, 2020. The replay dial-in numbers are (855) 859-2056 for domestic callers and (404) 537-3406 for international callers. Please use the replay conference ID number 5682075.About Alphatec Holdings, Inc.Alphatec Holdings, Inc. (“ATEC”), through its wholly-owned subsidiaries, Alphatec Spine, Inc. and SafeOp Surgical, Inc., is a medical device company dedicated to revolutionizing the approach to spine surgery through clinical distinction. ATEC architects and commercializes approach-based technology that integrates seamlessly with the SafeOp Neural InformatiX System to provide real-time, objective nerve information that can enhance the safety and reproducibility of spine surgery. Additional information can be found at www.atecspine.com.Forward-Looking StatementsStatements made during the investor events referenced herein may contain "forward-looking statements" within the meaning of the Private Securities Litigation Reform Act of 1995 that involve risks and uncertainty. Such statements are based on management's current expectations and are subject to many risks and uncertainties that could cause actual results to differ materially from those described in the forward-looking statements. These and other forward-looking statements are not guarantees of future results and are subject to risks, uncertainties, and assumptions that could cause actual results to differ materially from those expressed in any forward-looking statements. A list and description of such factors, risks and uncertainties can be found in the Company’s most recent annual report, and any subsequent quarterly and current reports, filed with the Securities and Exchange Commission. ATEC disclaims any intention or obligation to update or revise any forward-looking statements, whether as a result of new information, future events, or otherwise unless required by law.Investor/Media Contact:Josh Berg Investor Relations (760) 494-6790 ir@atecspine.comCompany Contact:Jeff Black Chief Financial Officer Alphatec Holdings, Inc. ir@atecspine.com
- 07/23/2020
|
BidaskClub Upgrades Alphatec (NASDAQ:ATEC) to “Hold”
- Alphatec (NASDAQ:ATEC) was upgraded by stock analysts at BidaskClub from a “sell” rating to a “hold” rating in a note issued to investors on Thursday, BidAskClub reports. Several other equities analysts have also weighed in on ATEC. Zacks Investment Research lowered Alphatec from a “buy” rating to a “hold” rating in a report on Friday, […]
- 07/16/2020
|
Patent Filings Roundup: District Court Filings Soar, Juul Targets Copycats and More NHK Spring Denials
- It was a banner week in the district courts, with 110 new filings, and the filings are showing signs of picking up—rather than slowing down—amidst the COVID pandemic.
- 07/15/2020
|
Analysts Estimate Alphatec (ATEC) to Report a Decline in Earnings: What to Look Out for
- Alphatec (ATEC) doesn't possess the right combination of the two key ingredients for a likely earnings beat in its upcoming report. Get prepared with the key expectations.
- 07/15/2020
|
3 “Strong Buy” Penny Stocks That Could Deliver Massive Returns
- Investor focus has landed squarely on the surge in new COVID-19 cases and its threat to economic reopenings, but there’s another possibility being ignored. According to Morgan Stanley equity strategist Mike Wilson, even though the market is expecting economic activity to decline, earnings could get a major boost.“Cautious investors may be overlooking the potential for operating leverage to fuel an earnings rebound... Aggressive cost-cutting in a downturn is what creates the powerful operating leverage when the economy recovers,” Wilson commented.While unemployment has skyrocketed during the coronavirus crisis, Wilson argues operating leverage was already dropping before the pandemic’s onset. “It’s also a classic feature of late-cycle economic expansions. My point is that many companies were already exhibiting negative operating leverage pre-COVID-19. This gives me confidence that Q2 will likely be the trough for earnings growth,” he explained.Bearing this in mind, some investors are on the hunt, looking to snap up compelling names before shares re-embark on an upward trajectory. For the more risk-tolerant, focus has locked in on penny stocks, or tickers trading for less than $5 per share. The appeal is clear; the bargain price tag means you can get more bang for your buck and even what feels like inconsequential share price appreciation can result in huge percentage gains.What’s the flip side? Minor share price depreciation can fuel major percentage losses. By nature of these massive movements, penny stocks are notoriously volatile.Using TipRanks’ database, we identified three penny stocks the pros believe could see explosive gains in the coming months. Not to mention each one gets a “Strong Buy” consensus rating from the analyst community.Daré Bioscience, Inc. (DARE)Focused on identifying and advancing cutting-edge therapies, Daré Bioscience’s products could provide women with additional choices, improved outcomes as well as options that are easier to use. Its strong pipeline and $1.00 share price have scored it substantial praise from the pros on Wall Street.One of these DARE bulls is Aegis Capital’s Nathan Weinstein. Citing its DARE-BV1 asset as a key component of his bullish thesis, the analyst tells investors that DARE had kicked off its pivotal trial for the candidate in patients with bacterial vaginosis (BV) earlier than he previously expected.Speaking to the therapy’s potential, DARE-BV1 is a bio-adhesive formulation of clindamycin phosphate 2% that, in a previous proof-of-concept study, generated an 86% clinical cure rate of BV. The trial, "DARE-BVFREE", is a randomized, double-blind, placebo-controlled pivotal Phase 3, and will enroll 240 patients across multiple sites in the U.S., with the primary endpoint being clinical cure (resolution of signs and symptoms). Weinstein points out that the therapy has already been given both Fast Track and QIDP designations. “Topline data is anticipated to be released this year, and, if the study is successful, we expect an NDA application to be filed in 2021,” the analyst added.On top of this, DARE’s pipeline features two other promising lead assets including Ovaprene, a monthly non-hormonal contraceptive, and Sildenafil Cream, designed for the treatment of female sexual arousal disorder (FSAD).Commenting on the pipeline, Weinstein stated, “We think the diversified, women's health-focused pipeline is undervalued relative to what we view as the upside potential, given: (1) the company's proven ability to strike sizable partnership deals, (2) the uniqueness of the assets that address what we view as unmet needs in the market, (3) the appeal of having multiple shots on goal, and (4) the possibility that FSAD proves to be a larger TAM than is currently appreciated.”If that wasn’t enough, the company is also developing a user-controlled long-acting reversible contraceptive device called DARE-LARC1, with the product already receiving funding from the Bill & Melinda Gates Foundation.To this end, Weinstein rates DARE shares a Buy along with a $5 price target. This figure conveys his confidence in DARE’s ability to soar 403% in the coming year. (To watch Weinstein’s track record, click here)Turning now to the rest of the Street, other analysts are on the same page. With 5 Buys and no Holds or Sells, the word on the Street is that DARE is a Strong Buy. Given its $4.50 average price target, upside of 350% could be in store for investors. (See DARE stock analysis on TipRanks)Alphatec Holdings (ATEC)When it comes to Alphatec Holdings, it has undergone a transformation thanks to its new management team, with it now operating as an innovative procedural-driven spine company. Based on this revamp and its $4.45 share price, major returns could be on the horizon, according to Northland Capital’s Jason Wittes. Wittes tells clients the restructuring that has taken place over the last two years, which included the sale of its international business and a shift away from lower end distributors that were associated with lower profit and controversial Physician Owned Distributors (PODs), has enabled it to build strong R&D; and sales teams as well as attract Key Opinion Leaders (KOLs). “Combined with a highly differentiated product portfolio, we think Alphatec is now positioned for significant growth,” he commented.Looking at its product portfolio, the company has given it a major face-lift during this transformational period. Wittes points out that 12 products were unveiled in 2019 alone, with each being designed around specific spinal fusion approaches.“SafeOP, the Company’s novel nerve monitoring platform is unique in its ability to monitor nerve health in real time, not just position, for improving safety and reproducibility—especially with minimally invasive lateral procedures, where there is no direct visualization of the nerves,” the analyst added.The good news doesn’t end there. ATEC plans to launch its Prone Transposes (PTP) lateral procedure at the North American Spinal Society (NASS) annual meeting in November. Reflecting a new approach to lateral fusions, PTP involves placing the patient in a prone position (stomach) versus on their side.Calling PTP a “game changer for lateral and ATEC," Wittes noted, “This approach increases the natural lordotic curvature of the spine for better alignment and cage placement, but also saves time by eliminating the need for patient repositioning when following up with decompression and/ or posterior fixation after the cage is placed (at least 45 minutes of OR time). This is a significant improvement over traditional lateral approaches, including NUVA’s recently launched X360, which attempts to save time by keeping the patient on their side.”Everything that ATEC has going for it prompted Wittes to rate the stock an Outperform (i.e. Buy) along with a $9 price target. This target implies shares could climb 100% higher in the next twelve months. (To watch Wittes’ track record, click here)Do other analysts agree with Wittes? They do. Only Buy ratings, 4, in fact, have been issued in the last three months, so the consensus rating is a Strong Buy. At $8.38, the average price target indicates shares could appreciate by 85% in the year ahead. (See Alphatec stock analysis on TipRanks)Axovant Gene Therapies (AXGT)With its innovative gene therapies, Axovant wants to transform the way in which neurodegenerative diseases are treated. Trading for $3.14 per share, several members of the Street believe that its price tag and technology platform make it a must-watch name.Part of the excitement surrounding AXGT is related to its lead asset, AXO-LENTI-PD. The company recently revealed that the enrollment of the higher-dose cohort of its Phase 2 SUNRISE-PD trial for the candidate in Parkinson's disease has been completed, with the data readout slated for Q4 2020. Speaking to the likelihood of success, the results from the lower-dose cohort were impressive, to say the least.Among AXGT’s fans is Cantor analyst Kristen Kluska. Highlighting that there aren’t many players using gene therapy to target Parkinson's disease, she argues that its use of a lentiviral vector also sets it apart. Thanks to the large payload capacity, this vector could potentially include three genes that encode enzymes needed for the endogenous dopamine synthesis (TH, CH1 and AADC).Expounding on this, Kluska stated, “As it relates to durability, we think there is evidence from ProSavin, where follow-up data has been published up to eight years for some patients (as a reminder ProSavin is considered part of a single development program with AXO-LENTI-PD, as the company has discussed with the agency)… While early (and in small patient numbers), Axovant has established greater improvements from the highest dose of ProSavin in AXO-LENTI-PD.” As a result, the readout in Q4 could serve as a major catalyst for shares.More than 2 million people suffer from the disease in the U.S. and the EU, and thus, Kluska thinks the candidate has blockbuster potential. “We think that this program remains the largest market opportunity for a gene therapy product that is unpartnered... Even with other competing gene therapies, given the market size we believe there is room for many players,” the analyst explained.To this end, Kluska rates AXGT an Overweight (i.e. Buy) along with an $11 price target, which implies nearly 250% upside potential from current levles. (To watch Kluska’s track record, click here)Most other analysts also take a bullish approach. AXGT’s Strong Buy consensus rating breaks down into 6 Buys and a lone Hold. Additionally, the $13.67 average price target, which is more aggressive than Kluska’s, puts the upside potential at a whopping 375%. (See Axovant stock-price forecast on TipRanks)To find good ideas for penny stocks trading at attractive valuations, visit TipRanks’ Best Stocks to Buy, a newly launched tool that unites all of TipRanks’ equity insights.
- 07/13/2020
|
Could The Alphatec Holdings, Inc. (NASDAQ:ATEC) Ownership Structure Tell Us Something Useful?
- The big shareholder groups in Alphatec Holdings, Inc. (NASDAQ:ATEC) have power over the company. Large companies...
- 07/03/2020
|
Canaccord Genuity Downgrades AxoGen (AXGN) to Hold - Markets
- Canaccord Genuity analyst Kyle Rose downgraded AxoGen (AXGN – Research Report) to Hold yesterday and set a price target of
- 07/02/2020
|
TELA Bio (TELA) Received its Third Buy in a Row - Markets
- After Jefferies and JMP Securities gave TELA Bio (NASDAQ: TELA) a Buy rating last month, the company received another Buy,
- 07/01/2020
|
Analysis on COVID-19 Related Markets: Interventional Spine Devices Market 2020-2024 | Increasing Incidences Of Spine Disorders to Augment Growth | Technavio
- The Global Interventional Spine Devices Market will grow by $ 2.31 bn during 2020-2024
- 07/01/2020
|
Alphatec (NASDAQ:ATEC) Stock Rating Lowered by BidaskClub
- Alphatec (NASDAQ:ATEC) was downgraded by research analysts at BidaskClub from a “hold” rating to a “sell” rating in a research note issued on Friday, BidAskClub reports. Several other research analysts have also recently commented on ATEC. ValuEngine upgraded shares of Alphatec from a “hold” rating to a “buy” rating in a report on Wednesday, April […]
- 06/28/2020
|
Hedge Funds Are Still Buying Alphatec Holdings Inc (ATEC)
- We at Insider Monkey have gone over 821 13F filings that hedge funds and prominent investors are required to file by the SEC The 13F filings show the funds' and investors' portfolio positions as of March 31st, near the height of the coronavirus market crash. In this article, we look at what those funds think […]
- 06/27/2020
|
Bank of New York Mellon Corp Sells 92,637 Shares of Alphatec Holdings Inc (NASDAQ:ATEC)
- Bank of New York Mellon Corp reduced its holdings in shares of Alphatec Holdings Inc (NASDAQ:ATEC) by 38.2% during the first quarter, according to the company in its most recent disclosure with the Securities and Exchange Commission (SEC). The institutional investor owned 149,668 shares of the medical technology company’s stock after selling 92,637 shares during […]
- 06/22/2020
|
Benzinga's Top Upgrades, Downgrades For June 18, 2020
- Upgrades * Goldman Sachs changed the rating for CNO Financial Group Inc (NYSE: CNO) from Neutral to Buy. In the first quarter, CNO Finl Gr showed an EPS of $0.58, compared to $0.41 from the year-ago quarter. The stock has a 52-week-high of $20.93 and a 52-week-low of $8.79. CNO Finl Gr's stock last closed at $14.93 per share. * Credit Suisse changed the rating for Church & Dwight Co Inc (NYSE: CHD) from Neutral to Outperform. For the first quarter, Church & Dwight Co had an EPS of $0.83, compared to year-ago quarter EPS of $0.70. The stock has a 52-week-high of $80.99 and a 52-week-low of $47.98. Church & Dwight Co's stock last closed at $75.35 per share. * DA Davidson upgraded the stock for MKS Instruments Inc (NASDAQ: MKSI) from Neutral to Buy. For the first quarter, MKS Instruments had an EPS of $1.54, compared to year-ago quarter EPS of $1.12. The stock has a 52-week-high of $122.30 and a 52-week-low of $66.87. MKS Instruments's stock last closed at $109.75 per share. * For Amedisys Inc (NASDAQ: AMED), Benchmark upgraded the stock from Hold to Buy. For the first quarter, Amedisys had an EPS of $1.05, compared to year-ago quarter EPS of $1.11. The stock has a 52-week-high of $218.44 and a 52-week-low of $115.41. Amedisys's stock last closed at $179.88 per share. * For Cloudflare Inc (NYSE: NET), Morgan Stanley upgraded the stock from Underweight to Equal-Weight. Interestingly, in the first quarter, Cloudflare's EPS was ($0.04). The stock has a 52-week-high of $36.00 and a 52-week-low of $14.50. Cloudflare's stock last closed at $35.81 per share. * RBC Capital upgraded the stock for Paylocity Holding Corp (NASDAQ: PCTY) from Sector Perform to Outperform. For the third quarter, Paylocity Holding had an EPS of $0.83, compared to year-ago quarter EPS of $0.60. The stock has a 52-week-high of $150.73 and a 52-week-low of $66.98. Paylocity Holding's stock last closed at $134.38 per share. * Barclays upgraded the stock for Pinnacle West Capital Corp (NYSE: PNW) from Equal-Weight to Overweight. In the first quarter, Pinnacle West Capital showed an EPS of $0.27, compared to $0.16 from the year-ago quarter. The stock has a 52-week-high of $105.51 and a 52-week-low of $60.05. Pinnacle West Capital's stock last closed at $76.24 per share. * For Zscaler Inc (NASDAQ: ZS), Morgan Stanley upgraded the stock from Underweight to Equal-Weight. Zscaler earned $0.07 in the third quarter, compared to $0.05 in the year-ago quarter. The stock has a 52-week-high of $112.73 and a 52-week-low of $35.00. Zscaler's stock last closed at $106.18 per share. Downgrades * For Brighthouse Financial Inc (NASDAQ: BHF), Goldman Sachs downgraded the stock from Buy to Neutral. Brighthouse Financial earned $2.60 in the first quarter, compared to $2.21 in the year-ago quarter. The stock has a 52-week-high of $48.25 and a 52-week-low of $12.05. Brighthouse Financial's stock last closed at $31.90 per share. * Goldman Sachs downgraded the stock for Principal Financial Group Inc (NASDAQ: PFG) from Neutral to Sell. Interestingly, in the first quarter, Principal Financial Group's EPS was $1.15. The stock has a 52-week-high of $60.81 and a 52-week-low of $23.31. Principal Financial Group's stock last closed at $42.85 per share. * Citigroup changed the rating for Bank OZK (NASDAQ: OZK) from Buy to Neutral. In the first quarter, Bank OZK showed an EPS of $0.09, compared to $0.86 from the year-ago quarter. The stock has a 52-week-high of $31.76 and a 52-week-low of $14.20. Bank OZK's stock last closed at $24.30 per share. * Wells Fargo changed the rating for Accenture PLC (NYSE: ACN) from Overweight to Equal-Weight. Accenture earned $1.91 in the second quarter, compared to $1.73 in the year-ago quarter. The stock has a 52-week-high of $216.39 and a 52-week-low of $137.15. Accenture's stock last closed at $205.14 per share. * DZ Bank changed the rating for American Express Co (NYSE: AXP) from Buy to Hold. In the first quarter, American Express showed an EPS of $1.98, compared to $2.01 from the year-ago quarter. The stock has a 52-week-high of $138.13 and a 52-week-low of $67.00. American Express's stock last closed at $103.96 per share. * Berenberg changed the rating for Carnival Corp (NYSE: CCL) from Hold to Sell. For the second quarter, Carnival had an EPS of ($3.30), compared to year-ago quarter EPS of $0.66. The stock has a 52-week-high of $53.34 and a 52-week-low of $7.80. Carnival's stock last closed at $19.08 per share. * For DHT Holdings Inc (NYSE: DHT), Stifel downgraded the stock from Buy to Hold. In the first quarter, DHT Holdings showed an EPS of $0.44, compared to $0.12 from the year-ago quarter. The stock has a 52-week-high of $8.83 and a 52-week-low of $4.77. DHT Holdings's stock last closed at $5.54 per share. Initiations * Northland Capital Markets initiated coverage on Alphatec Holdings Inc (NASDAQ: ATEC) with an Outperform rating. The price target for Alphatec Holdings is set at $9.00. In the first quarter, Alphatec Holdings showed an EPS of ($0.33), compared to ($0.29) from the year-ago quarter. The stock has a 52-week-high of $7.93 and a 52-week-low of $2.19. Alphatec Holdings's stock last closed at $4.88 per share. * With a rating of Buy, SunTrust Robinson Humphrey initiated coverage on Editas Medicine Inc (NASDAQ: EDIT). The price target is set at $45.00 for Editas Medicine. For the first quarter, Editas Medicine had an EPS of ($0.69), compared to year-ago quarter EPS of ($0.60). The stock has a 52-week-high of $34.37 and a 52-week-low of $14.01. Editas Medicine's stock last closed at $29.89 per share. * Janney Capital initiated coverage on Invitation Homes Inc (NYSE: INVH) with a Buy rating. The price target for Invitation Homes is set at $34.00. For the first quarter, Invitation Homes had an EPS of $0.34, compared to year-ago quarter EPS of $0.33. The stock has a 52-week-high of $32.70 and a 52-week-low of $15.64. Invitation Homes's stock last closed at $28.41 per share. * Baird initiated coverage on CoStar Group Inc (NASDAQ: CSGP) with an Outperform rating. The price target for CoStar Gr is set at $755.00. CoStar Gr earned $2.44 in the first quarter, compared to $2.53 in the year-ago quarter. The stock has a 52-week-high of $746.70 and a 52-week-low of $500.24. CoStar Gr's stock last closed at $689.44 per share. * Stifel initiated coverage on Health Catalyst Inc (NASDAQ: HCAT) with a Buy rating. The price target for Health Catalyst is set at $36.00. In the first quarter, Health Catalyst earned ($0.16). The stock has a 52-week-high of $49.85 and a 52-week-low of $17.48. Health Catalyst's stock last closed at $29.69 per share. * RBC Capital initiated coverage on Tyler Technologies Inc (NYSE: TYL) with an Outperform rating. The price target for Tyler Technologies is set at $375.00. For the first quarter, Tyler Technologies had an EPS of $1.25, compared to year-ago quarter EPS of $1.22. The stock has a 52-week-high of $382.92 and a 52-week-low of $210.80. Tyler Technologies's stock last closed at $339.17 per share. * With a rating of Buy, Mizuho initiated coverage on Neoleukin Therapeutics Inc (NASDAQ: NLTX). The price target is set at $21.00 for Neoleukin Therapeutics. Neoleukin Therapeutics earned ($0.18) in the first quarter, compared to ($0.09) in the year-ago quarter. The stock has a 52-week-high of $15.35 and a 52-week-low of $2.53. Neoleukin Therapeutics's stock last closed at $13.52 per share. * MKM Partners initiated coverage on QEP Resources Inc (NYSE: QEP) with a Buy rating. The price target for QEP Resources is set at $3.00. In the first quarter, QEP Resources showed an EPS of $0.21, compared to $0.15 from the year-ago quarter. The stock has a 52-week-high of $7.42 and a 52-week-low of $0.26. QEP Resources's stock last closed at $1.60 per share.See more from Benzinga * 14 Energy Stocks Moving In Thursday's Pre-Market Session * Kroger: Q1 Earnings Insights * 16 Financial Services Stocks Moving In Thursday's Pre-Market Session(C) 2020 Benzinga.com. Benzinga does not provide investment advice. All rights reserved.
- 06/18/2020
|
Edited Transcript of ATEC earnings conference call or presentation 11-May-20 8:30pm GMT
- Q1 2020 Alphatec Holdings Inc Earnings Call
- 06/10/2020
|
Head to Head Analysis: Alphatec (NASDAQ:ATEC) and Nevro (NASDAQ:NVRO)
- Alphatec (NASDAQ:ATEC) and Nevro (NYSE:NVRO) are both medical companies, but which is the better investment? We will contrast the two businesses based on the strength of their institutional ownership, risk, dividends, profitability, analyst recommendations, earnings and valuation. Earnings and Valuation This table compares Alphatec and Nevro’s revenue, earnings per share and valuation. Gross Revenue Price/Sales […]
- 06/10/2020
|
Russell Investments Group Ltd. Cuts Position in Alphatec Holdings Inc (NASDAQ:ATEC)
- Russell Investments Group Ltd. decreased its position in Alphatec Holdings Inc (NASDAQ:ATEC) by 40.6% during the first quarter, according to the company in its most recent filing with the Securities and Exchange Commission (SEC). The fund owned 113,006 shares of the medical technology company’s stock after selling 77,093 shares during the quarter. Russell Investments Group […]
- 06/10/2020
|
Spinal Fusion Devices Market Size 2020 | Industry Analysis, Share, Upcoming Trends, Segmentation, Opportunities and Forecast 2025
- Jun 02, 2020 (Market Insight Reports) --
A recent report on Spinal Fusion Devices Market provides a detailed analysis of the industry size, revenue forecasts...
- 06/02/2020
|
Orthopedic Devices Market Analysis as per the Latest COVID-19 Impact
- Jun 02, 2020 (Heraldkeepers) --
New York, June 2, 2020:You will get latest updated report as per the COVID-19 Impact on this industry. Our updated reports...
- 06/02/2020
|
Alphatec Holdings, Inc. (ATEC) CEO Patrick Miles on Q1 2020 Results - Earnings Call Transcript
- Alphatec Holdings, Inc. (NASDAQ:ATEC) Q1 2020 Results Earnings Conference Call May 11, 2020, 04:30 PM ET Company Participants Patrick Miles - Chairman and Chief
- 05/12/2020
|
Alphatec Holdings Inc (ATEC) Q1 2020 Earnings Call Transcript
- Image source: The Motley Fool. Alphatec Holdings Inc (NASDAQ: ATEC)Q1 2020 Earnings CallMay 11, 2020, 4:30 p.m. ETContents: Prepared Remarks Questions and Answers Call Participants Prepared Remarks: OperatorGood afternoon, everyone, and welcome to Alphatec's First Quarter 2020 Financial Results and Recent Corporate Highlights Announcement.
- 05/12/2020
|
Alphatec Holdings Q1 EPS $(0.330) May Not Compare To $(0.210) Estimate, Sales $29.100M Miss $29.420M Estimate
|
ATEC Reports First Quarter 2020 Financial Results and Recent Corporate Highlights
- • New Product Adoption Drives U.S. Revenue Growth of 27%• Additional $35 Million Capital Commitment Provides Runway for Continued Execution CARLSBAD, Calif., May 11, 2020 --.
- 05/11/2020
|
Ansell: Global Leader In Protective Gloves And Germ Prevention
- Ansell is a leading manufacturer in gloves and hazmat suits. The stock is reasonably priced. Ansell should continue to do well with an emphasis on fighting germ
- 05/08/2020
|
OPA : ce qu'il faut savoir début mai
- Renforcement du contrôle des investissements étrangers en France, renonciation d'Alphatec Holdings à l'offre publique sur EOS Imaging, réussite de l'OPA de Schneider Electric sur RIB Software, mesures ciblées préconisées par l'AMF en direction de l'activisme actionnarial : tout ce qu'il faut savoir.
Les nouveautés
Investissements étrangers en France (IEF) : la règlementation se durcit
- 05/04/2020
|
OPA : ce qu’il faut savoir début mai
- Les nouveautés Investissements étrangers en France (IEF) : la règlementation se durcit. Un arrêté du 27 avril 2020, publié au Journal Officiel du 30 avril, intègre désormais les biotechnologies à la liste des secteurs d’activité dans lesquels les investissements étrangers sont soumis à autorisation préalable.
- 05/04/2020
|
Bourse : six actions à acheter et autant à vendre après une semaine écourtée
- Découvrez ci-dessous tous les conseils boursiers de la rédaction du Revenu cette semaine. Les actualités les plus marquantes (FDJ, Hermès, Renault, Vinci, Scor...) font l'objet d'un développement spécifique, accessible en cliquant sur les liens hypertextes. Alors que le CAC 40 reste fébrile malgré son rebond de 22% sur ses plus-bas de mars, nous conseillons six actions à l'achat, six à la vente et neuf sont à conserver.
- 05/02/2020
|
Investir en Bourse autrement avec les obligations convertibles
- Avec la versatilité des marchés, les obligations convertibles (OC), qui ont cet avantage de pouvoir être échangées contre des actions de la société émettrice, retrouvent un regain d’intérêt. Bloc "A lire aussi" En raison de leur caractère hybride, ces véhicules permettent en effet d’accompagner le développement d’une société cotée, mais en prenant des risques plus limités qu’en achetant les actions équivalentes.
- 05/01/2020
|
The Global Spinal Fusion Device Market is expected to grow from USD 4,986.23 Million in 2018 to USD 7,496.28 Million by the end of 2025 at a Compound Annual Growth Rate (CAGR) of 5.99%
- New York, April 29, 2020 -- Reportlinker.com announces the release of the report "Global Spinal Fusion Device Market - Premium Insight, Competitive News Feed Analysis, Company.
- 04/29/2020
|
Perkins Capital Management Inc Buys Interpace Biosciences Inc, CareDx Inc, Gilead Sciences Inc, ...
|
Alphatec to Report First Quarter 2020 Financial Results on May 11, 2020
- CARLSBAD, Calif., April 28, 2020 -- Alphatec Holdings, Inc. (Nasdaq: ATEC) (“ATEC” or the “Company”), a provider of innovative spine surgery solutions dedicated to.
- 04/28/2020
|
Analysts Are Bullish on Top Healthcare Stocks: Axsome Therapeutics (AXSM), Alphatec Holdings (ATEC)
- There's a lot to be optimistic about in the Healthcare sector as 2 analysts just weighed in on Axsome Therapeutics (AXSM) and Alphatec Holdings (ATEC)
- 04/28/2020
|
Alphatec to Report First Quarter —…—… Financial Results on May ––, —…—…
|
EN DIRECT DES MARCHES : Airbus, Air-France KLM, Renault, Orange, EOS Imaging, Adidas, Boeing, Facebook...
|
Alphatec Terminates Agreement to Acquire EOS Imaging
|
En mai, fais ce qu'il te plaît ?
|
EOS IMAGING : Alphatec jette l'éponge
- (AOF) - Mauvaise nouvelle pour EOS Imaging et ses actionnaires. L'américain Alphatec jette l'éponge
- 04/27/2020
|
ATEC Terminates Agreement to Acquire EOS Imaging
- Alphatec Holdings, Inc. (“ATEC” or the “Company”) (ATEC), a medical device company dedicated to revolutionizing the approach to spine surgery, announced today that it has terminated the Tender Offer Agreement (“TOA”), dated February 26, 2020, under which it was to acquire EOS imaging, SA (“EOS”), for up to $88 million, plus debt retirement of $33.9 million, in a combination of cash and equity. Based upon its assessment, ATEC concluded that a “Material Adverse Effect” (as defined in the TOA) has occurred, resulting in circumstances that are no longer conducive to completion of the transaction described in the TOA.
- 04/27/2020
|
ALPHATEC HOLDINGS RÉSILIE L'ACCORD CONCLU AVEC EOS IMAGING PORTANT SUR LE DÉPÔT D'UN PROJET D'OFFRE PUBLIQUE
- Paris, le 27 avril 2020, 7h00 - EOS imaging (Euronext, FR0011191766 - EOSI - Eligible PEA-PME), ("EOS"), pionnier des solutions d'imagerie 2D / 3D et des solutions logicielles pour la modélisation anatomique 3D et la planification chirurgicale, a été informé par Alphatec Holdings, Inc. ("ATEC"), le 24 avril 2020, de la résiliation par ce dernier de l'accord relatif au dépôt d'un projet d'offre publique ("Tender Offer Agreement") précédemment annoncé, aux termes duquel ATEC s'était engagé à lancer une offre publique visant EOS
- 04/27/2020
|
ATEC Terminates Agreement to Acquire EOS Imaging
|
OrthoPediatrics Corp. Is Now Wildly Overvalued
- KIDS trades at over 10x 2019 revenues while comparable orthopedic companies trade at an average around 3x revenues. The company could post a decline in revenue
- 04/25/2020
|
Alphatec (NASDAQ:ATEC) Lowered to Hold at Zacks Investment Research
- Zacks Investment Research lowered shares of Alphatec (NASDAQ:ATEC) from a buy rating to a hold rating in a report published on Thursday morning, Zacks.com reports. According to Zacks, “Alphatec Holdings, Inc. is a medical technology company focused on the design, development, manufacturing and marketing of products for the surgical treatment of spine disorders. The Company’s […]
- 04/20/2020
|
Alphatec (NASDAQ:ATEC) Stock Rating Upgraded by ValuEngine
- Alphatec (NASDAQ:ATEC) was upgraded by equities research analysts at ValuEngine from a “hold” rating to a “buy” rating in a research report issued on Wednesday, ValuEngine reports. Several other research firms have also commented on ATEC. Lake Street Capital boosted their price target on Alphatec from $10.00 to $15.00 and gave the stock a “buy” […]
- 04/17/2020
|
H.C. Wainwright Reiterates Buy on Alphatec Holdings, Lowers Price Target to $7.5
|
Analysts' Top Healthcare Picks: Neuronetics (STIM), Alphatec Holdings (ATEC)
- There's a lot to be optimistic about in the Healthcare sector as 3 analysts just weighed in on Neuronetics (STIM), Alphatec Holdings (ATEC) and X4
- 04/09/2020
|
Analysts’ Top Healthcare Picks: Neuronetics (STIM), Alphatec Holdings (ATEC)
- There’s a lot to be optimistic about in the Healthcare sector as 3 analysts just weighed in on Neuronetics (STIM
- 04/09/2020
|
ATEC Prelim. Adj. Cash Balance As Of Mar. 31, 2020 $47.5M
|
ATEC Highlights Draw Down Of $20M Credit Facility From Squadron Capital
|
ATEC Sees Q1 Sales $29.6M-$30M vs $29.9M Estimate
|
ATEC Announces Preliminary First Quarter 2020 Revenue Results And Provides Business Update
- Alphatec Holdings, Inc. (“ATEC” or the “Company”) (ATEC), a medical device company dedicated to revolutionizing the approach to spine surgery, announced today preliminary revenue results for the first quarter ended March 31, 2020, and provided a business update on its response to the COVID-19 pandemic. Preliminary, unaudited first quarter 2020 results reflect U.S. revenue growth of 25% to 26%.
- 04/08/2020
|
Zimmer Biomet Holdings (ZBH) Received its Third Buy in a Row
- After Stifel Nicolaus and Leerink Partners gave Zimmer Biomet Holdings (NYSE: ZBH) a Buy rating last month, the company received another Buy, this time
- 04/07/2020
|
Zimmer Biomet Holdings (ZBH) Received its Third Buy in a Row
- After Stifel Nicolaus and Leerink Partners gave Zimmer Biomet Holdings (NYSE: ZBH) a Buy rating last month, the company received
- 04/07/2020
|
Edited Transcript of ATEC earnings conference call or presentation 5-Mar-20 9:30pm GMT
- Q4 2019 Alphatec Holdings Inc Earnings Call
- 04/02/2020
|
Ansell share price surges 18% higher on positive business update
- The Ansell Limited (ASX: ANN) share price is surging this morning following a business update in light of the growing coronavirus crisis.
- 03/29/2020
|
Alphatec Holdings Enters Oversold Territory
- Alphatec Holdings has been on a bit of a cold streak lately, but there might be light at the end of the tunnel for this overlooked stock.
- 03/25/2020
|
Alphatec Holdings Enters Oversold Territory
|
Stocks That Hit 52-Week Lows On Monday
- On Monday morning, 720 companies hit new 52-week lows.
Noteworthy Mentions:
The largest company by market cap to set a new 52-week low was Alphabet (NASDAQ: GOOGL)...
- 03/23/2020
|
Alphatec Holdings Inc (ATEC) CEO Patrick Miles Bought $—'—,5…… of Shares
|
Executive Vice President of Marketing & Development Brian Snider Just Bought Shares In Alphatec Holdings, Inc. (NASDAQ:ATEC)
- Investors who take an interest in Alphatec Holdings, Inc. (NASDAQ:ATEC) should definitely note that the Executive Vice...
- 03/14/2020
|
Alphatec Holdings Inc (ATEC) EVP, Strat. Mktg. & Prod. Dev. ...
|
Globus Medical Announces $200 Million Share Repurchase Program
- Globus Medical, Inc. (GMED), a leading musculoskeletal solutions company, today announced the Board of Directors authorized the repurchase of $200 million of the Company’s common stock. “We believe the recent stock market volatility has created a significant divergence between the intrinsic value of
- 03/11/2020
|
Alphatec Holdings, Inc. Just Reported Yearly Earnings: Have Analysts Changed Their Mind On The Stock?
- Alphatec Holdings, Inc. (NASDAQ:ATEC) shares fell 5.0% to US$5.56 in the week since its latest full-year results. It...
- 03/08/2020
|
H.C. Wainwright Reiterates Buy on Alphatec Holdings, Raises Price Target to $9.5
|
Analysts Offer Insights on Healthcare Companies: Alphatec Holdings (ATEC) and BioCryst (BCRX)
- There's a lot to be optimistic about in the Healthcare sector as 2 analysts just weighed in on Alphatec Holdings (ATEC) and BioCryst (BCRX) with bullish
- 03/06/2020
|
Analysts Offer Insights on Healthcare Companies: Alphatec Holdings (NASDAQ: ATEC) and BioCryst (NASDAQ: BCRX)
- There’s a lot to be optimistic about in the Healthcare sector as 2 analysts just weighed in on Alphatec Holdings
- 03/06/2020
|
Wall Street Analysts Are Bullish on Top Healthcare Picks
- There's a lot to be optimistic about in the Healthcare sector as 2 analysts just weighed in on Oncolytics Biotech (ONCY) and Alphatec Holdings (ATEC) with
- 03/06/2020
|
Wall Street Analysts Are Bullish on Top Healthcare Picks
- There’s a lot to be optimistic about in the Healthcare sector as 2 analysts just weighed in on Oncolytics Biotech
- 03/06/2020
|
Alphatec Sees FY20 Sales $130M-$134M vs $130.9M Estimate
|
Alphatec Holdings Q4 EPS $(0.28) Misses $(0.19) Estimate, Sales $31.143M Beat $30.83M Estimate
|
ATEC Reports Fourth Quarter and Full Year 2019 Financial Results
- U.S. Revenue Grew Nearly 30% Year-Over-Year for the Full YearAnd 35% Year-Over-Year in the Fourth Quarter CARLSBAD, Calif., March 05, 2020 -- Alphatec Holdings, Inc. (“ATEC”.
- 03/05/2020
|
Alphatec Holdings, Inc. to Host Earnings Call
- NEW YORK, NY / ACCESSWIRE / March 5, 2020 / Alphatec Holdings, Inc. (ATEC) will be discussing their earnings results in their 2019 Fourth Quarter Earnings call to be held on March 5, 2020 at 4:30 PM Eastern ...
- 03/05/2020
|
Company News for Mar 3, 2020
- Companies in the news are: FTSV, MINI, KPTI ATEC
- 03/03/2020
|
108 Biggest Movers From Yesterday
|
Analysts' Top Healthcare Picks: Biogen (BIIB), Alphatec Holdings (ATEC)
- There's a lot to be optimistic about in the Healthcare sector as 2 analysts just weighed in on Biogen (BIIB) and Alphatec Holdings (ATEC) with bullish
- 03/02/2020
|
Analysts’ Top Healthcare Picks: Biogen (BIIB), Alphatec Holdings (ATEC)
- There’s a lot to be optimistic about in the Healthcare sector as 2 analysts just weighed in on Biogen (
BIIB
–
Research Report
) and Alphatec Holdings (
ATEC
–
Research Report
) with bullish sentiments.
Biogen (BIIB)
In a report issued on February 28
- 03/02/2020
|
OPA, OPE : EOS Imaging et Agta Record dans le viseur
- Alphatec a annoncé un projet d'offre alternative sur EOS Imaging, alors que le feu vert à l'acquisition d'une participation majoritaire dans le capital d'Agta Record a été donné. En revanche, la perspective d'une offre publique s'éloigne pour EuropaCorp
- 03/02/2020
|
55 Stocks Moving In Monday's Mid-Day Session
|
A Peek Into The Markets: US Stock Futures Plunge Amid Coronavirus Fears
- Pre-open movers
U.S. stock futures traded lower in early pre-market trade. South Korea confirmed 256 new coronavirus cases on Thursday, while China reported an additional 327 new...
- 02/28/2020
|
ATEC Announces Agreement to Acquire EOS imaging
- Alphatec Holdings, Inc. (“ATEC” or the “Company”) (ATEC), a medical device company dedicated to revolutionizing the approach to spine surgery, announced today that it has entered into an agreement to acquire EOS imaging, SA, for a purchase price of up to $88 million, plus debt retirement of $33.9 million, in a combination of cash and equity. EOS imaging is a leader in outcome-improving orthopedic medical imaging and software solutions, and is globally recognized for its rapid, low dose, biplanar full-body imaging and 3D modeling capabilities.
- 02/28/2020
|
Alphatec Holdings to Acquire EOS imaging in Cash and Stock Deal Valued at Up to $121.9M
|
Alphatec to Report Fourth Quarter and Fiscal Year 2019 Financial Results on March 5th 2020, and Participate in Upcoming Investor Conference
- The Company will host a live webcast and audiocast of the conference on Thursday, March 5, 2020, at 1:30 p.m. PT / 4:30 p.m. ET. The live webcast will be accessible at: https://edge.media-server.com/mmc/p/cocjhkoy. An audiocast of the conference call will be available domestically at (877) 556-5251 and internationally at (720) 545-0036.
- 02/20/2020
|
Phillips Financial Management, Llc Buys Vanguard S&P 5…… Value, iShares Core S&P ...
|
Bernzott Capital Advisors Buys ServiceMaster Global Holdings Inc, Sells Carbonite Inc, Alphatec ...
|
EAM Investors, LLC Buys ChemoCentryx Inc, Nordic American Tankers, Douglas Dynamics Inc, Sells ...
|
Need To Know: Alphatec Holdings, Inc. (NASDAQ:ATEC) Insiders Have Been Buying Shares
- It is not uncommon to see companies perform well in the years after insiders buy shares. Unfortunately, there are also...
- 02/03/2020
|
25 Medical Devices Stocks Moving In Tuesday's Session
|
SI-Bone (SIBN) Gets a Buy Rating from Canaccord Genuity
- Canaccord Genuity analyst Kyle Rose maintained a Buy rating on SI-Bone (SIBN – Research Report) today and set a price
- 01/24/2020
|
23 Medical Devices Stocks Moving In Thursday's Session
|
27 Medical Devices Stocks Moving In Tuesday's Session
|
85 Biggest Movers From Yesterday
|
Alphatec sees FY20 revenue $130M-$134M, consensus $127.66M ATEC
- Alphatec sees FY20 revenue $130M-$134M, consensus $127.66M ATEC
- 01/13/2020
|
Alphatec sees FY19 revenue $113.1M-$113.5M, consensus $111.12M ATEC
- Alphatec sees FY19 revenue $113.1M-$113.5M, consensus $111.12M ATEC
- 01/13/2020
|
Alphatec sees Q4 revenue $32M-$32.4M, consensus $30.04M ATEC
- Alphatec sees Q4 revenue $32M-$32.4M, consensus $30.04M ATEC
- 01/13/2020
|
ATEC Announces Preliminary 2019 Revenue Results and 2020 Revenue Outlook
- Alphatec Holdings, Inc. (“ATEC” or the “Company”) (ATEC), a medical device company dedicated to revolutionizing the approach to spine surgery, announced today preliminary revenue results for the fourth quarter and full year ended December 31, 2019, and provided revenue guidance for the full year 2020.
- 01/13/2020
|
Alphatec Holdings Sees FY2020 Sales $130M-134M vs $127.66M Est
|
Did Business Growth Power Alphatec Holdings's (NASDAQ:ATEC) Share Price Gain of 226%?
- The most you can lose on any stock (assuming you don't use leverage) is 100% of your money. But if you pick the right...
- 12/20/2019
|
Stocks That Hit 52-Week Highs On Wednesday
|
Hedge Funds Have Never Been This Bullish On Alphatec Holdings Inc (ATEC)
- Hedge funds and large money managers usually invest with a focus on the long-term horizon and, therefore, short-lived dips or bumps on the charts, usually don't make them change their opinion towards a company. This time it may be different. During the fourth quarter of 2018 we observed increased volatility and a 20% drop in […]
- 12/16/2019
|
3 Monster Growth Stocks That Make Great Picks for 2020
- What’s always in style on the Street? Growth. Investors are constantly window shopping on Wall Street to pinpoint the names that represent the crème-de-la-crème when it comes to the ability to post long-term gains. This makes sense as growth leads to profits, which in turn can lift share prices.However, given the market’s record breaking performance in 2019, it isn’t always easy to spot the stocks poised to climb higher and yield handsome returns in the years to come. That’s where the analysts can help. Using the Stock Screener tool from TipRanks, we were able to zero in on 3 stocks with stellar long-term growth narratives backed by Wall Street analysts. We’re talking about enough support to earn a “Strong Buy” consensus rating here. If that wasn’t enticing enough, all of the names boast at least 20% upside potential from the current share price. Here’s the scoop. Alphatec Holdings, Inc. (ATEC)This med tech company has disrupted the market with its innovative products for the surgical treatment of spine disorders. After skyrocketing 193% since the start of the calendar year, analysts are betting that ATEC can continue its impressive run in 2020.Part of the bullish sentiment surrounding the company is due to its strong Q3 performance that sped past the revenue consensus estimate. ATEC reported that quarterly revenue hit $29.2 million, surpassing the $26.4 million estimate. Management pointed to the domestic strategic distribution segment, which was up 52% in the quarter, as the driver here. Not to mention full year revenue guidance was bumped up from $104 million-$109 million to $109 million-$112 million. While Lake Street’s Brooks O'Neil notes that some drag from terminated distributor relationships and from legacy products remains, ATEC has made a significant effort to turn things around. “Specifically, Pat Miles, CEO and his team are spine experienced and taking significant steps to strengthen the Company's distributor relationships (key in spine) and to revitalize its product line…While we recognize there remains work to be done, we are absolutely convinced this team will complete the job,” he explained. The analyst adds that its product lineup lends itself to ATEC’s strong position in the $7 billion U.S. spine market. “We believe the market is ripe for innovation and ATEC is targeting complex spine procedures, minimally invasive surgeries and biologics, collectively the fastest growing segments of the market,” he commented. Specifically, O’Neil cites ATEC’s SafeOp platform, it’s technology that eliminates the need for a technician or other neuromonitoring professional to monitor the risk of nerve injury during spinal surgeries, as especially promising. Taking all this into consideration, the four-star analyst kept the rating as a Buy and boosted the price target from $7 to $10. At this updated target, shares could jump 49% in the next twelve months. (To watch O’Neil’s track record, click here)Similarly, the rest of the Street takes a bullish approach when it comes to ATEC. Given the 4 Buys and no Holds or Sells assigned in the last three months, the consensus comes in unanimously as a Strong Buy. On top of this, the $9 average price target indicates 30% upside potential. (See Alphatec stock analysis on TipRanks) Telaria Inc. (TLRA) As Telaria has already achieved 202% growth year-to-date, the Street is watching the video content software company very closely. While shares dipped after management left its forecast for 2019 revenue unchanged, some members of the Street argue that TLRA still has a lot going for it. Its connected TV (CTV) business increased a whopping 115% year-over-year and boasts margins in the high-80% range. As a result, Stephens analyst Kyle Evans believes that this segment can take TLRA to new heights. “We believe rapidly changing consumer behavior combined with numerous, new AVOD product launches will create a large ad-supported CTV market, where TLRA’s leading, independent CTV tech platform will continue to grow rapidly,” he wrote in a note to clients. Bearing this in mind, he maintained the Overweight recommendation as well as the $11 price target, implying 33% upside. (To watch Evans’ track record, click here)Meanwhile, Lake Street’s Mark Argento highlights recent publisher wins and its continued innovation as making TLRA a stand-out despite soft gross margins. The company racked up deals in the quarter that included Crown Media and Plex TV in the U.S., its first deal in Japan with a leading broadcaster, three large publishers in Canada and a large consortium of Australian publishers. Additionally, TLRA unveiled Audience Connect, its new group of addressable audience-based buying solutions as well as new features to improve transparency and communications. Based on these factors, Argento stayed with a Buy rating and an $11 price target, the same as Evans’ estimate. (To watch Argento’s track record, click here) All in all, other Wall Street analysts are on the same page. With 100% Street support, the message is clear: TLRA is a Strong Buy. The Street does however see a bit less upside potential, 25% to be exact. (See Telaria stock analysis on TipRanks) Crocs, Inc. (CROX)The famous foam shoe designer has been impressing analysts left and right ahead of the holiday shopping season.Mitch Kummetz of Pivotal Research was surprised by the degree in which Crocs was able to beat the estimates for third quarter sales and EPS. During the quarter, sales reached $313 million, exceeding the $302 million consensus estimate. EPS flew past the 40 cent Street forecast, coming in at 57 cents. “In short, the company won’t quantify its spring prebooks, but we suspect they’re even stronger than we had previously anticipated, as retailers are allocating a lot more of their open-to-buy to Crocs clogs in particular,” the analyst stated. This prompted him to not only reiterate his bullish call but also raise the price target by $5 to $44, suggesting 24% upside potential. (To watch Kummetz’s track record, click here)Like Kummetz, Piper Jaffray analyst Erinn Murphy likes what she’s seeing, citing Crocs as one of her favorite Holiday ideas. Jibbitz, or charms to accessorize the company’s shoes, offer a wealth of opportunity according to Murphy. “All in, we see 14% EBIT margin by 2021 (vs. our current 13.5%) as plausible if Jibbitz momentum continues. We have observed Jibbitz at retail partners in store and online in recent weeks and believe broader distribution could meaningfully accelerate charm penetration in the coming quarters,” she noted. The analyst also tells investors that U.S. search trends have reaccelerated quarter to date, with its collaboration with artist Post Malone still on the horizon. Based on statements from the CMO, the launch could be the company’s largest ever. To this end, the analyst maintained the Overweight rating and $44 price target. (To watch Murphy’s track record, click here) The rest of the Street appears to echo the two analysts’ sentiment. 4 Buys and 1 Hold add up to a Strong Buy consensus rating. In addition, the $43 average price target brings the potential twelve-month gain to 20%. (See Crocs stock analysis on TipRanks)
- 12/08/2019
|
Alphatec (ATEC) Presents At Piper Jaffray Healthcare Conference - Slideshow
|
ATEC Announces Commercial Launch of the SafeOp Neural InformatiX System™
- Alphatec Holdings, Inc. (“ATEC” or the “Company”) (ATEC), a medical device company dedicated to revolutionizing the approach to spine surgery, announced today the commercial release of the SafeOp Neural InformatiX System (“SafeOp”), which has been designed to seamlessly integrate critical neural information into ATEC procedural solutions. “Today, we are launching the first reflection of the innovation that we expect to deliver through the SafeOp platform: a powerful technology that meets an unmet need for objective, intraoperative neural information during surgery,” said Pat Miles, Chairman and Chief Executive Officer. The SafeOp Neural InformatiX System has been engineered with electromyography (EMG) and somatosensory evoked potentials (SSEP) to provide surgeons with actionable information regarding both the location and the health of nerves at risk during surgery.
- 11/26/2019
|
Stocks That Hit 52-Week Highs On Tuesday
|
Stocks That Hit 52-Week Highs On Monday
|
ATEC to Participate in The Canaccord Genuity MedTech and Diagnostics Forum and The Piper Jaffray 31st Annual Healthcare Conference
- Jeff Black, Chief Financial Officer, will participate in one-on-one meetings at the Canaccord Genuity MedTech and Diagnostics Forum on Thursday, November 21, 2019, at The Westin Grand Central Hotel in New York City. Pat Miles, Chairman and Chief Executive Officer, will present at the Piper Jaffray 31st Annual Healthcare Conference on Wednesday, December 4th, 2019, at 3:30 p.m. E.T., at the Lotte New York Palace Hotel in New York City. A live audio webcast of the Piper Jaffray Conference presentation, along with copies of the accompanying presentation materials, will be available online from the Investor Relations page of the Company's corporate website at www.atecspine.com.
- 11/12/2019
|
Stocks That Hit 52-Week Highs On Monday
|
Stocks That Hit 52-Week Highs On Friday
|
Alphatec Holdings, Inc. 2019 Q3 - Results - Earnings Call Presentation
|
Alphatec Holdings Q3 EPS $(0.26) Misses $(0.22) Estimate, Sales $29.201M Beat $26.37M Estimate
|
Perkins Capital Management Inc Buys HTG Molecular Diagnostics Inc, BioLife Solutions Inc, Inuvo ...
|
Alphatec Enhances its Lateral Portfolio With the Commercial Launch of Approach-Specific Innovation
|
Alphatec Holdings (ATEC) Investor Presentation - Slideshow
|
Canaccord Genuity Initiates Coverage On Alphatec Holdings with Buy Rating, Announces $7 Price Target
|
Alphatec Announces Favorable Judgment In NuVasive v. Miles Lawsuit
|
Alphatec Received DA 510(k) Approval For Fusion Device With Bone Graft, Lumbar
|
Stocks That Hit 52-Week Highs Of Monday
|
Stocks That Set New 52-Week Highs Thursday
|
New 52-Week-High Achievers For Tuesday Morning
|
Piper Jaffray Initiates Coverage On Alphatec Holdings with Overweight Rating, Announces $7 Price Target
|
Alphatec Holdings, Inc. Announces Closing of Public Stock Offering and Full Exercise of ...
|
88 Biggest Movers From Yesterday
|
Alphatec Holdings Prices 10.9M Share Common Stock Offering At $4.60/Share
|
ENPH, FEYE and TWOU among after hour movers
|
Companies That Achieved 52-Week Highs Friday
|
Alphatec Holdings, Inc. 2019 Q2 - Results - Earnings Call Slides
|
Alphatec Raises FY19 Sales Guidance From $98M-$103M To $104M-$109M vs $100.9M Estimate
|
Alphatec Announces Commercial Launch Of InVictus MIS And Open Spinal Fixation Systems
|
Alphatec Highlights Commercial Launch Of ALIF IdentiTi Implant
|
Alphatec (ATEC) May Report Negative Earnings: Know the Trend Ahead of Next Week's Release
|
Alphatec Holdings S-3 Shows Registration For ~4.839M Share Common Stock Offering Via Selling Shareholders
|
Alphatec Holdings (ATEC) Presents At Raymond James Life Sciences & MedTech Conference - Slideshow
|
Alphatec Announces Updated Presentation Date and Time at the Raymond James Life Sciences and ...
|
Medtronic To Acquire Titan Spine For Implant Surface Tech
|
Alphatec Holdings, Inc. 2019 Q1 - Results - Earnings Call Slides
|
Alphatec Holdings Q1 EPS $(0.29) Misses $(0.21) Estimate, Sales $24.555M Beat $24.3M Estimate
|
Alphatec Holdings: Turnaround Still In Early Innings
|
Earnings Preview: Alphatec (ATEC) Q1 Earnings Expected to Decline
|
68 Biggest Movers From Yesterday
|
50 Stocks Moving In Tuesday's Mid-Day Session
|
Alphatec Announces Sales Leadership Appointment And Successful Closing of Expanded Credit ...
|
Alphatec Holdings Inc (ATEC) Files –…-K for the Fiscal Year Ended on December '–, —…–8
|
Daily Insider Ratings Round Up 3/12/19
|
Alphatec Holdings EVP Howell Buys 100,000 @ Avg Price: $2.59
|
Alphatec Announces Participation At Canaccord and Cowen Investor Conferences in March
|
Alphatec Holdings Sees FY19 Sales $98M-$103M vs $99.95M Est.
|
Alphatec Shares Up 11.8%; FDA Access Data Site Shows 510(k) Premarket Notification For IdentiTi Porous Ti Interbody System
|
Alphatec Reports FDA Clearance For Automated SafeOp Neuromonitoring System To Address Unmet Needs In Spine Surgey
|
NUVA and NGL among premarket gainers
|
